Smartphone phenotype collection for diagnostic screening of mild cognitive impairment
智能手机表型收集用于轻度认知障碍的诊断筛查
基本信息
- 批准号:10478979
- 负责人:
- 金额:$ 74.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-30 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdultAffectAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAmyloidAppleCOVID-19CTF1 geneCellular PhoneClinicClinicalCognitionCognitiveCollectionComputer Vision SystemsCyclophosphamideDataData CollectionData SetDementiaDetectionDevelopmentDiseaseEarly DiagnosisEarly InterventionEpisodic memoryEquipmentEvaluationEye MovementsFaceFingersFrequenciesGeneral PractitionersGenetic RiskGoalsHealthHomeImpaired cognitionImpairmentIndividualInfrastructureInstitutional Review BoardsInterventionJournalsLanguageLewy Body DiseaseMachine LearningManuscriptsMeasurementMeasuresMedical DeviceMindModelingMonitorMotionMotorMovementNeurologistNeuropsychological TestsNeuropsychologyPaperParticipantPatient MonitoringPatientsPeer ReviewPerformancePeriodicityPersonsPhasePhenotypeProductionPublicationsReadingReportingResearchResolutionSaccadesScanningSensitivity and SpecificitySignal TransductionSmall Business Innovation Research GrantStreamSurveysTabletsTest ResultTestingThumb structureTimeTremorValidationVisionVisitVoiceWorkWorld Health Organizationarmbasecloud platformcognitive abilitycognitive changecognitive performancecognitive testingcohortcommercializationdesigndiagnostic screeningdigitaldigital healthearly screeningexperiencefunctional declinehandheld mobile devicehome testimprovedinnovationmild cognitive impairmentmobile applicationmobile sensornegative affectnovelpeaceperformance testsrecruitrisk prediction modelscreeningsensorsmartphone Applicationtouchscreentv watchingusabilityvisual searchvisual tracking
项目摘要
PROJECT SUMMARY
In this Phase II SBIR project, Parabon NanoLabs will complete the development, validation and
commercialization of CTX, a revolutionary smartphone- and tablet-based cognitive testing
platform for collection and analysis of measurements of cognitive performance (“phenotypes”).
Traditionally, cognitive assessments are performed in a clinic using either simple surveys that
assess only some aspects of cognition or expensive, single-purpose equipment such as eye tracking
stations. Such testing lacks the frequency and precision needed to detect subtle early changes that
signal the onset of mild cognitive impairment (MCI) or early-symptomatic dementia. Instead,
CTX will take full advantage of mobile sensors (e.g., audio, video, touchscreen, and motion) to
enable in-depth cognitive testing anytime, anywhere. Regular use of CTX will allow a clearer
picture of each user's cognitive abilities to emerge, enabling early detection of subtle changes. CTX
is not intended to replace neurologists but instead to extend their reach by allowing regular,
widespread screening for improved disease detection and patient monitoring. The long-range goal
of CTX is to allow aging adults to monitor and manage their cognitive health more effectively and
to provide pre-symptomatic indicators of pending dementia to patients and their clinicians, thus
enabling early intervention and planning.
After a highly successful Phase I project, CTX already enables rapid development of mobile tests
that can capture raw sensor streams in a synchronized fashion and transmit them to a cloud server
for subsequent analysis and reporting. Sophisticated analytics pipelines have been developed to
convert these sensor streams into cognitive phenotypes (e.g., extracting eye movement data from
selfie video taken during a cognitive test). Using the CTX framework, the Parabon team has
already developed an Apple® iOS® mobile app with proof-of-principle tests for assessing verbal
recall, eye movement, motor function, and episodic memory.
In Phase II, we propose to develop two new suites of CTX tests for one-time cognitive impairment
screening and cognitive performance monitoring, as well as phenotype extraction pipelines for
each. We will evaluate tests in normal and affected cohorts to determine usability, user retention
and whether resulting phenotypes enable accurate cognitive assessments by clinicians. Our
specific aims are to (1) Develop new and engaging cognitive tests and pipelines for assessing visual
search and targeting, expressive and receptive language, motor movement and episodic memory;
(2) Validate measures in cognitively normal and impaired cohorts; and (3) Analyze and prepare
data for publication and premarket submissions to the FDA.
项目摘要
在这个第二阶段SBIR项目中,Parabon NanoLabs将完成开发,验证和
CTX的商业化,这是一种革命性的基于智能手机和平板电脑的认知测试
用于收集和分析认知表现(“表型”)测量的平台。
传统上,认知评估在诊所中使用简单的调查来进行,
只评估认知的某些方面或昂贵的单一用途设备,如眼动追踪
站的这种测试缺乏检测微妙的早期变化所需的频率和精度,
提示轻度认知障碍(MCI)或早期症状性痴呆的发作。相反地,
CTX将充分利用移动的传感器(例如,音频、视频、触摸屏和运动),
随时随地进行深入的认知测试。定期使用CTX将允许更清晰的
每个用户的认知能力的图片出现,使早期发现微妙的变化。CTX
并不是为了取代神经科医生,而是为了扩大他们的范围,
广泛筛查,以改善疾病检测和患者监测。远景目标
CTX的目的是让老年人更有效地监测和管理他们的认知健康,
为患者及其临床医生提供即将发生痴呆症的症状前指标,
以便及早干预和规划。
在一个非常成功的第一阶段项目之后,CTX已经能够快速开发移动的测试
可以同步捕获原始传感器流并将其传输到云服务器
以便随后进行分析和报告。已经开发了复杂的分析管道,
将这些传感器流转换成认知表型(例如,提取眼球运动数据
在认知测试期间拍摄的自拍视频)。使用CTX框架,Parabon团队
已经开发了一款Apple® iOS®移动的应用程序,该应用程序具有用于评估口头语言的原理验证测试
回忆、眼球运动、运动功能和情景记忆。
在第二阶段,我们建议开发两套新的CTX测试,用于一次性认知障碍
筛查和认知表现监测,以及表型提取管道,
每个.我们将在正常和受影响的队列中评估测试,以确定可用性、用户保留率
以及所得到的表型是否能够使临床医生进行准确的认知评估。我们
具体目标是:(1)开发新的、吸引人的认知测试和管道,用于评估视觉
搜索和目标,表达和接受语言,运动和情景记忆;
(2)在认知正常和受损的队列中进行测量;和(3)分析和准备
用于向FDA发表和提交上市前申请的数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven L Armentrout其他文献
Steven L Armentrout的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven L Armentrout', 18)}}的其他基金
Parametric design software for nanostructured CRISPR payloads
用于纳米结构 CRISPR 有效负载的参数化设计软件
- 批准号:
10602823 - 财政年份:2023
- 资助金额:
$ 74.26万 - 项目类别:
A nanoengineering platform for programmable gene editing therapies against rare diseases
用于针对罕见疾病的可编程基因编辑疗法的纳米工程平台
- 批准号:
10699037 - 财政年份:2023
- 资助金额:
$ 74.26万 - 项目类别:
A multitargeted nanocarrier inhibitor of undruggable transcription factors for treating castration resistant prostate cancer
用于治疗去势抵抗性前列腺癌的不可成药转录因子的多靶点纳米载体抑制剂
- 批准号:
10415002 - 财政年份:2021
- 资助金额:
$ 74.26万 - 项目类别:
A multitargeted nanocarrier inhibitor of undruggable transcription factors for treating castration resistant prostate cancer
用于治疗去势抵抗性前列腺癌的不可成药转录因子的多靶点纳米载体抑制剂
- 批准号:
10252316 - 财政年份:2021
- 资助金额:
$ 74.26万 - 项目类别:
Smartphone phenotype collection for diagnostic screening of mild cognitive impairment
智能手机表型收集用于轻度认知障碍的诊断筛查
- 批准号:
10255750 - 财政年份:2018
- 资助金额:
$ 74.26万 - 项目类别:
Mixed-Ligand Targeting of a Nano-Pharmaceutical Against GBM Stem Cells
纳米药物的混合配体靶向 GBM 干细胞
- 批准号:
8518927 - 财政年份:2011
- 资助金额:
$ 74.26万 - 项目类别:
Mixed-Ligand Targeting of a Nano-Pharmaceutical Against GBM Stem Cells
纳米药物的混合配体靶向 GBM 干细胞
- 批准号:
8201250 - 财政年份:2011
- 资助金额:
$ 74.26万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 74.26万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 74.26万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 74.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 74.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 74.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




